Article
First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.
Cancer communications (London, England) - 28 Jul 2018
Yu Xiangyang, Zhang Xuewen, Zhang Zichen, Lin Yongbin, Wen Yingsheng, Chen Yongqiang, Wang Weidong, Zhang Lanjun
Abstract excerpt
BACKGROUND: The antitumour efficacy of tyrosine kinase inhibitors (TKIs) in lung cancer patients with compound epidermal growth factor receptor (EGFR) mutations has not been resolved. Our study summarizes a single institutional experience of first-generation TKI therapy for lung cancers with compound EGFR mutations. METHODS: A total of 106 consecutive patients with tumours bearing compound EGFR mutations were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.